Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

The company was founded in 1998 and successfully listed on the Shenzhen Stock Exchange in May 2012. After nearly 20 years of accumulation and development, Dongcheng Pharmaceutical has now developed into a large-scale pharmaceutical enterprise group covering the four major fields of biochemical raw materials, proprietary Chinese medicines, chemicals, and nuclear drugs, integrating drug R&D, production, and sales. The company is in the pharmaceutical manufacturing industry; the company's main business is divided into three segments: API business, formulation business, and nuclear medicine business. The company's main products include heparin sodium raw materials, chondroitin sulfate, injectable nadroparin calcium injections, hydrocortisone sodium succinate for injections, pharyngitis drops, antipruritic granules, pediatric cough relief granules, etc. Corporate honors: In February 2017, the company won the title of “2016 Outstanding Enterprise for Fulfilling Social Responsibility Second Prize”; in December 2017, the company's chondroitin sulfate product won the title of “2017 Excellent Biochemical Biopharmaceutical Brand” by China Biochemical and Pharmaceutical Industry Association; in December 2017, the company won the 2017 Shandong Top 100 Enterprise Brand Value; in June 2017, Yunke Pharmaceutical's “Industrialization of Iodine [125I] Sealed Seed Source, a Novel Targeted Interventional Drug for Solid Tumors” was listed as the “Sichuan Major Scientific and Technological Achievement Transformation Project”; 2017 In August of this year, Yunke Pharmaceutical's technology center was recognized as the “Sichuan Enterprise Technology Center”, “Shandong Top 100 Private Enterprise Innovators”, and the 61st in the “2024 China Pharmaceutical R&D Strength Ranking Top 100” by Pharmaceutical Intelligence Network.